


## PHARMACEUTICAL 2018

## ARRAY BIOPHARMA INC Rank 172 of 349





## PHARMACEUTICAL 2018

## ARRAY BIOPHARMA INC Rank 172 of 349

The relative strengths and weaknesses of ARRAY BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARRAY BIOPHARMA INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 161% points. The greatest weakness of ARRAY BIOPHARMA INC is the variable Research and Development, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is -169%, being 109% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	270,177
Cost of Goods Sold	35,395
Intangible Assets	0
Liabilities, Current	69,551
Liabilities, Non-Current	197,867
Other Assets	836
Other Compr. Net Income	-83
Other Expenses	0
Other Liabilities	0
Other Net Income	-14,740
Property and Equipment	8,132
Research and Development	178,199
Revenues	150,852
Selling, General and Administrative Expense	39,336

Output Variable	Value in 1000 USD
Assets	279,145
Liabilities	267,418
Expenses	252,930
Stockholders Equity	11,727
Net Income	-116,818
Comprehensive Net Income	-116,860
Economic Capital Ratio	-169%